Abstract
OX40L blockade synergizes with sirolimus to prevent GVHD by controlling effector T cell activation while supporting T reg reconstitution.
Funding Information
  • National Heart, Lung, and Blood Institute (award307997, HL11879)
  • National Heart, Lung, and Blood Institute (award307998, HL56067)
  • National Heart, Lung, and Blood Institute (award308000, HL095791)
  • National Institute of Allergy and Infectious Diseases (award307999, AI34495)
  • National Institute of Allergy and Infectious Diseases (award308001, AI051731)

This publication has 79 references indexed in Scilit: